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Beta-Radiation for Coronary In-Stent Restenosis
Donald R. Latchem, MBBS, Philip Urban,*†MD, Jean-Jacques Goy, MD,
Edoardo De Benedetti, MD, Alessia Pica, MD, Philippe Coucke, MD, and Eric Eeckhout, MD, PhD
To determine the feasibility and safety of an intracoronary beta-radiation device in
preventing the recurrence of in-stent restenosis (ISR) after successful angioplasty, we
studied 37 patients treated with beta-radiation (30-mm strontium-90 source) after angio-
plasty. The mean reference diameter was 2.9 6 0.5 mm, and 62% of lesions were diffuse,
including four total occlusions. Beta-radiation was successfully delivered in 36 of 37
(97%) cases. Over the course of 7.1 6 4.5 mo follow-up, there were no myocardial
infarctions and three deaths: one from preexisting malignancy, one from progressive
cardiac failure, and one from sudden cardiac death. Target vessel revascularization (TVR)
was performed in seven of 36 (19%) patients. Thirty patients underwent angiography at 6
mo; three (10%) experienced restenosis (diameter stenosis > 50%) at the target site, four
(13%) had edge stenoses, and two (7%) had late (> 1 mo) thrombotic occlusions.
Beta-radiation for ISR is associated with encouragingly low rates of target lesion reste-
nosis and TVR. Further improvements are needed to solve the limitations of the edge
effect and late occlusion. Cathet. Cardiovasc. Intervent. 51:422–429, 2000.
© 2000 Wiley-Liss, Inc.
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INTRODUCTION
Restenosis after percutaneous coronary intervention
limits the long-term therapeutic benefit of this procedure
and results in significant morbidity and additional costs.
Restenosis occurs in 30–60% [1,2] of cases after balloon
angioplasty and is symptomatic in the majority of pa-
tients, necessitating a second attempt at revasculariza-
tion. It is thought to result from two concurrent mecha-
nisms of action in response to mechanical injury to the
vessel wall: intimal hyperplasia and negative arterial
remodeling (vessel shrinkage), a result of early elastic
recoil and, later, adventitial fibrosis. In two landmark
studies, the coronary stent has been shown to reduce
significantly the incidence of restenosis compared with
balloon angioplasty alone [3,4]. This fact, together with
improved immediate angiographic outcome and reduced
acute closure, has led to a dramatic increase in their use
worldwide since the early 1990s; the majority of centers
now deploy stents in 70–80% of cases. Intravascular
ultrasonographic studies have taught us that stents pri-
marily prevent restenosis by eliminating negative remod-
eling [5]. Stents, however, do not limit intimal hyperpla-
sia. In fact, the opposite is true [5]. Excessive intimal
hyperplasia is thought to account for the phenomenon of
in-stent restenosis that occurs in 10–35% of cases. Sev-
eral different percutaneous approaches can be attempted
to treat this condition: balloon angioplasty [6,7], stenting
[8–10], rotational atherectomy [11], excimer laser angio-
plasty [12,13], and cutting balloon [14]. While immedi-
ate angiographic and clinical outcomes are usually good,
the reported recurrent restenosis rates at 6 mo range
widely (22–85%). Target vessel revascularization rates
at 1 yr are 11–19% for focal lesions (# 10 mm), 35% for
diffuse lesions (. 10 mm), 50% for proliferative lesions
(. 10 mm and extending beyond the stent borders), 83%
for total occlusions, and 100% for saphenous vein grafts
[6–20].
Intracoronary radiotherapy is a new method that has
been shown to reduce significantly neointimal formation
in animal models of restenosis [21]. Several clinical trials
in humans have confirmed the efficacy and safety of
gamma- and beta-radiation in limiting restenosis at the
target site after balloon angioplasty in both de novo and
restenotic lesions, compared with controls [22–25]. We
report our experience with 37 patients using in-stent
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restenosis with a novel catheter-based beta-emitting de-
vice (Beta-Cath; Novoste Europe SA/NV, Brussels, Bel-
gium).
METHODS
Study Design and Patient Population
Between October 1998 and December 1999, we en-
rolled 37 consecutive patients with in-stent restenosis
and evidence of ischemia. The study protocol was ap-
proved by the ethics committee at our institution, and
written informed consent was obtained from each patient.
Procedure
All patients received intra-arterial or intravenous hep-
arin sufficient to maintain an activated clotting time of
between 300 and 350 sec. Large lumen (0.86 inch) 8F
guiding catheters (Vector; Medtronic Intervention Vas-
cular Inc., Danvers, MA) were used. The lesions were
dilated with standard 20-mm balloon catheters in the
usual way. Additional stenting was not undertaken unless
indicated for significant dissection, proximal or distal to
the target lesion. When necessary, the stents were always
deployed after intracoronary radiotherapy. The use of the
glycoprotein IIb/IIIa inhibitor abciximab was left to the
discretion of the operator. Following the procedure, all
patients were continued on aspirin at 100 mg/day. Ticlo-
pidine or clopidogrel was given for the first month if
additional stenting was required; as of March 1999, it
was decided to give all patients 300 mg of clopidogrel on
the day of the procedure, followed by 75 mg/day for
3–6 mo.
The Beta-Radiation Device
The Beta-Cath device consists of a hand-held, multi-
ple-use transfer device, a 5F delivery catheter, and a
30-mm source train of strontium-90 seeds (a pure beta-
emitter) sealed in 12 independent cylinders. The safety
and feasibility of this device has been evaluated for de
novo lesions [22]. Following balloon angioplasty, the
delivery catheter is advanced over the standard 0.014-
inch guide wire, using the monorail channel, and placed
precisely across the lesion and barotraumatized segment
using proximal and distal radiopaque markers. The at-
tending radiation oncologist hydraulically delivers the
source train by a sterile water-filled syringe from the
transfer device to the target site through the closed-end
delivery catheter in a few seconds. The source is main-
tained at the target site by continuously applying gentle
pressure on the flushing syringe. The device is in a
closed-loop system; no fluid is injected into the coronary
artery, and the source train is never in contact with the
patient’s blood. The prescribed dose is 16 Gy at 2 mm
from the source for vessels of 2.7–3.3 mm in diameter or
20 Gy at 2 mm for vessels 3.4–4.0 mm. Upon comple-
tion of the procedure and retrieval of the source train into
the transfer device, only the delivery catheter needs to be
discarded. The source train is kept inside the transfer
device and placed in a radiation storage site until the next
procedure. During the entire procedure, two cardiolo-
gists, a radiation oncologist, and a physicist (to measure
the radiation activity) are present. No additional shield-
ing is required.
Angiography and Quantitative Coronary
Angiographic Analysis
Angiography was carried out in the same orthogonal
views before and after percutaneous transluminal coro-
nary angioplasty (PTCA) and radiotherapy and at fol-
low-up for each patient. In addition, efforts were made to
document each position of the angioplasty balloon and
source train on film (Fig. 1a–c). Following administra-
tion of intracoronary isosorbide dinitrate, a diastolic
frame with sharply defined edges without foreshortening
and overlap was selected for quantitative coronary anal-
ysis. The 8F guiding catheter was used as the calibration
standard. The percent diameter stenosis, the diameter of
the reference vessel, and the minimal luminal diameter of
the lesion segment were determined in the usual manner
using an edge-detection program (Advantage; General
Electric Medical Systems, Milwaukee, WI). In addition,
to analyze the effects of radiation at the edges of the
target lesion, we took these same measurements on se-
lected segments at varying distances both proximal and
distal to the lesion, using readily identifiable landmarks
(e.g., angulations, branch points, other stents). The seg-
ment of artery that was ballooned and/or irradiated was
considered the treated segment. Acute gain (in millime-
ers) was defined as the change in the target site’s min-
imal luminal diameter (MLD) from baseline to the result
immediately after the procedure. Late loss (in millime-
ters) was defined as the change in target site MLD from
immediately post-procedure to follow-up angiography.
The late loss index was defined as the ratio of late loss to
acute gain. Each angiogram was reviewed for the pres-
ence or absence of “geographic miss,” defined as a mar-
gi of radiation source/balloon overlap of, 5 mm at
both ends [26].
Follow-Up and End Points
Clinical follow-up was undertaken at 30 days and at
6–8 mo by telephone contact with the patient and/or the
treating physician. The following clinical end points
were evaluated during the study period: procedural suc-
cess and major adverse cardiac events (myocardial in-
farction, urgent or elective target vessel revasculariza-
tion, and death). Procedural success was defined as the
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successful delivery of the prescribed dose and residual
stenosis not greater than 30% (by visual estimation) of
the luminal diameter after PTCA without myocardial
infarction, death, or urgent target vessel revascularization
within 30 days of the index procedure. Myocardial in-
farction was defined as an elevation of the creatine kinase
and creatine kinase-MB levels more than twice the upper
limit of normal or by the appearance of pathological Q
waves on the electrocardiogram. Revascularization was
carried out at the discretion of the treating cardiologist.
Follow-up angiography was done at 6–8 mo after the
index procedure, unless the clinical situation warranted
earlier evaluation. The angiographic end point was reste-
nosis, defined as a percentage diameter stenosis of$
50%. All data were entered into a computerized database
and expressed as proportions or as means plus or minus
the standard deviation.
RESULTS
Study Population and Procedural Outcome
Thirty-seven consecutive patients were enrolled. The
baseline clinical and angiographic characteristics are shown
in Table I. The patients’ ages averaged 616 11 yr; 76%
were male, 22% had diabetes, 46% had disease affecting
more than one vessel, and 54% had New York Heart As-
sociation class III or IV angina. Thirty-four lesions were in
native coronaries, and the remaining three lesions were in
saphenous vein grafts. Eight patients (22%) had had more
than one recurrence at the same site. The mean reference
diameter was 2.96 0.5 mm, with a mean diameter stenosis
of 71.2 6 17.3%. Fifteen lesions (40%) were focal
(length# 10 mm), 14 (38%) were diffuse (length. 10 mm
within the stent), and four (11%) were proliferative (. 10
mm extending outside the stent). There were four (11%)
totally occluded stents, giving a mean lesion length of
14.66 10.4 mm. Balloon angioplasty was successful in all
cases. In four cases (11%) additional stent implantation was
necessary to treat dissection beyond the target site, and one
of these patients also received abciximab. No patients re-
ceived a stent within the stent. In one case (3%), placement
of the delivery catheter was unsuccessful after PTCA, be-
cause of proximal vessel tortuosity. This patient, who had
no complications, was excluded from clinical and angio-
graphic follow-up. The mean prescribed dose was 18.06
2.2 Gy at a distance of 2 mm from the source, with a mean
dwell time of 3.76 0.4 min. In six cases (16%) the operator
attempted to irradiate the full length of the lesion by first
placing the source train across the distal segment and then
repositioning the delivery catheter and source across the
proximal segment. This “pullback” maneuver resulted in a
short, middle segment of the lesion effectively receiving
twice the dose. Geographic miss during the index procedure
occurred in 17 cases (46%) and was unavoidable in most
cases (e.g., the lesion length exceeded the source length, or
additional stents were needed for dissection beyond the
target site). The four patients (11%) who underwent stenting
were given short courses of antiplatelet therapy (#1 mo),
but as of March 1999 all the subsequent 17 (46%) patients
received prolonged (3–6 mo) antiplatelet therapy. At 30
days there were no cases of subacute stent thrombosis,
target vessel revascularization, myocardial infarction, or
death. The procedural success rate was therefore 36 of 37
(97%).
Clinical Follow-up
At a mean clinical follow-up time of 7.16 4.5 mo,
there were no myocardial infarctions, and three patients
had died. One patient, who experienced a severe lesion
on the proximal left anterior descending artery at the
edge of the target site, died suddenly while awaiting
coronary bypass surgery. Another died from known, dis-
seminated prostatic carcinoma 6 mo after the procedure.
The third patient died from progressive cardiac failure at
21/2 mo, without signs of recurrent ischaemia. This last
patient, who was not a surgical candidate, had severe
three-vessel disease, three occluded bypass grafts, and an
ejection fraction of 0.28. The target lesion was the right
coronary artery, which was supplying collaterals to the
left coronary system and had been redilated seven times.
One patient had acute onset of new exertional angina, as
the result of late (. 1 mo) stent thrombotic occlusion
approximately 31/2 mo after the procedure. Target vessel
revascularization was necessary in seven of 36 (19.4%)
patients; a second PTCA was performed in four and
coronary artery bypass grafting in three.
TABLE I. Baseline Clinical and Angiographic Characteristics*
Total no. 37
Age (yr) 616 11
Male sex, no. (%) 28 (76%)
Diabetes, no. (%) 8 (22%)





Postinfarction, no. (%) 3 (8%)
Target lesion site
Left anterior descending artery 11 (30%)
Left circumflex artery 6 (16%)
Marginal 1 (3%)
Right coronary artery 16 (43%)
Saphenous vein graft 3 (8%)
Lesion length (mm) 14.6 10.4
Diffuse lesions, no. (%) 23 (62%)
*NYHA, New York Heart Association.
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Angiographic Follow-up and Quantitative
Coronary Analysis
Angiographic follow-up information was obtained for
30 of 36 (83%) patients at a mean time of 5.36 1.9 mo
(Table II). Two deaths occurred before angiographic
follow-up, two patients refused angiographic follow-up
(both were asymptomatic with negative results of func-
tional tests at 6 mo), and another two asymptomatic
patients were still to undergo angiography at the time of
writing. Target-site restenosis was found in three of 30
(10%), and all three showed signs of recurrent angina.
These three patients had had focal stenoses in native
Fig. 1. a: Coronary angiogram of a significant in-stent reste-
nosis in the left anterior descending coronary artery. b: Angio-
plasty with a 20-mm balloon. c: Position of the 30-mm source
train (between the radiopaque markers) within the delivery
catheter, with adequate overlap at either end of the stent. d: The
final result after angioplasty and irradiation. e: (see next page)
No significant restenosis at 6-mo follow-up.
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coronaries. Four (13%) other patients had new lesions
beyond the target site (but within the treated segment),
and two of them were symptomatic. Geographic miss
during the index procedure had occurred in three of these
patients. Two patients (7%) were found to have late
thrombotic occlusions (at 3.5 and 6, mo, respectively);
neither had had total occlusions originally.
On quantitative coronary analysis (Table 2), per-
formed on all nonoccluded treated segments, the MLD
went from 0.76 0.4 mm to 2.16 0.3 mm immediately
after treatment and then to 2.06 0.6 mm at follow-up,
with a late loss index of only 0.156 0.28 mm. The MLD
of the proximal and distal segments went from 2.66 0.7
mm and 2.06 0.5 mm to 2.66 0.7 mm and 2.16 0.4
mm, respectively, immediately after treatment and then
to 2.5 6 0.8 mm and 2.16 0.4 mm, respectively, at
follow-up. The cumulative distribution curves of the
MLD before and after angioplasty and at follow-up are
shown in Fig. 2, and it can be seen that late loss is small
in the majority of patients. In three patients, the MLD
was larger at follow-up compared with the result imme-
diately after angioplasty. Positive remodeling has been
described after radiation therapy of nonstented segments
[22]. In two of the three cases this could be explained by
inclusion of the stent borders in the lesion QCA analysis
(because the lesions extended beyond the stent). In one
patient, in whom the pullback maneuver had been per-
formed, marked positive remodeling (maximum diameter
of 5.1 mm on QCA) was observed in the segment that
had received the cumulative dose.
DISCUSSION
This study demonstrates the feasibility and safety of a
passively centered, catheter-based beta-radiation device
in preventing restenosis after balloon angioplasty in pa-
tients with in-stent restenosis. Our results are consistent
with those of other studies that document a lower than
expected recurrence rate in patients with in-stent reste-
nosis treated by intracoronary gamma- and, more re-
cently, beta-radiation. In a randomized placebo-con-
trolled trial of a catheter-based gamma-emitter (iridium-
192), Teirstein et al. [23] found a 6-mo angiographic
restenosis rate of 17% in patients with restenotic lesions
(62% with in-stent restenosis) compared with 54% in the
placebo group. In a similar study, the WRIST (Washing-
ton Radiation for In-stent Restenosis Trial) by Waksman
et al [24], also using a noncentered iridium-192 source, a
binary angiographic restenosis rate of 19% was reported,
versus 58% (P 5 0.001) in the placebo arm. This lower
restenosis rate in the treatment group was associated with
significantly fewer target lesion revascularization proce-
dures (13.8% vs. 63.1%) and fewer major adverse car-
diac events (29.2% vs. 67.7%) at 6 mo, compared with
controls.
Equally impressive reductions in these end points have
been reported with beta-radiation. Popma presented the
results of the Stents and Radiation Therapy (START)
trial [27], which utilized the same beta-radiation device
s in our study and documented a 66% reduction in
binary angiographic restenosis (14.2% vs. 41.2%;P ,
0.001) and 34% reduction in the need for target vessel
revascularization (16% vs. 24%;P 5 0.026) compared
with the placebo group. By way of contrast, Sabate´ et al.
[28], using the same beta-radiation device, had a recur-
rence rate of 53%, leading to a target vessel revascular-
ization rate of 47% in 18 patients with a history of at least
two recurrences of in-stent restenosis. They documented
geographic miss in 44% of all cases. Seventy-eight per-
cent of the recurrences were at the edge of the irradiated
area, and the vast majority (86%) of these edge recur-
Figure 1. (Continued.)
TABLE II. Immediate Outcomes and Follow-up
Procedural success 36/37 (97%)
Death 3/36 (8.3%)
Sudden cardiac death 1
Cardiac failure 1
Malignancy 1
Myocardial infarction 0/36 (0%)
Target vessel revascularization 7/36 (19.4%)
Coronary bypass grafting 3/36 (8.3%)
Balloon angioplasty 4/36 (11.1%)
6-mo angiographic follow-up 30/36 (83%)
Target lesion restenosis 3/30 (10%)
Edge recurrence 4/30 (13.3%)
Late stent occlusion 2/30 (6.7%)
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rences were in areas of documented geographic miss.
This “edge effect” is thought to be a consequence of
geographic miss, where a segment of artery is barotrau-
matized by the balloon but receives inadequate radiation
because it lies in the radiation dose “falloff” zone, allow-
ing the formation of intimal hyperplasia and negative
arterial remodeling [26]. It can be seen from our study
that the edge effect accounted for the majority of recur-
rences, including the patient who died suddenly. The
edge effect has been described in the other clinical trials
of both beta and gamma-emitting catheter-based devices
[24,25,27] and beta-emitting stents [29]. In START [27],
an additional 14.6% recurrences were at the edges in the
radiation arm, compared with only 4% of the placebo
group. In WRIST [24], 6-mo target lesion revasculariza-
tion was reported as 13.8% in the irradiated group but
target vessel revascularization was necessary in another
12.1%, whereas in the placebo group the two forms of
treatment differed by only 4.7%, suggesting an excess of
the edge effect in the treatment group.
Similarly, in the GAMMA 1 [25] trial, one-third of the
recurrences (10.8%) were at the stent edge in the irradi-
ated group, as opposed to only 6.8% of all recurrences in
the placebo group. The edge effect is even more apparent
with radioactive stents. In a dose-finding study, with
Palmaz-Schatz 153 and BX Isostent stents, restenosis at
the proximal and distal ends of the stent occurred in
43–62% of cases. In-stent intimal hyperplasia was mark-
edly reduced, giving the typical “candy wrapper” appear-
ance [29], presumably because the shoulder of the stent-
deploying balloon lies in the dose falloff zone. From our
study, we estimate that geographic miss results in a risk
of approximately 18% for the edge effect. This highlights
the importance of covering the entire balloon-injured
segment, with considerable overlap, when using intra-
coronary radiation. Heightened awareness of this prob-
lem and the availability of longer source trains in the near
future should translate into improved results.
Another important issue is that of late stent thrombo-
sis. One of our patients, who did not have a new stent
implanted, showed signs of this complication 5 days after
completing a 3-mo course of ticlopidine. The second,
who had had a 1-mo course of ticlopidine, did not expe-
rience angina and was found to have an occluded stent
only at angiographic follow-up. This phenomenon has
been observed in most intracoronary radiation studies,
with incidence rates between 5% and 15% (with the
highest incidence rates seen after stenting) [30,31]. In the
absence of radiotherapy, by way of comparison, total
occlusions have been documented in 4.1% of patients at
angiographic follow-up. In these cases, in-stent resteno-
sis is treated with balloon angioplasty and provisional
stenting [9]. It is now clear that arterial trauma invariably
follows balloon angioplasty and that radiotherapy delays
the natural healing process, including endothelialization
of the stent, leaving the artery and stent vulnerable to
thrombosis for a prolonged period of time [32,33]. It is
Fig. 2. Minimal luminal diameter cumulative distribution
curves. Pre, before angioplasty; Post, immediately after angio-
plasty, F/U, follow-up angiography.
TABLE III. Angiographic Results at 6 mo*
Pre-procedurea Post-procedurea Follow-upa,b
Reference vessel (mm) 2.96 0.5 2.86 0.4 2.96 0.4
Lesion MLD (mm) 0.76 0.4 2.16 0.3 2.06 0.6
Diameter stenosis (%) 71.26 12.3 24.86 10.6 30.26 19.3
Proximal segment MLD (mm) 2.6 0.7 2.66 0.7 2.56 0.8
Distal segment MLD (mm) 2.06 0.5 2.16 0.4 2.16 0.4
Change in minimal luminal diameter
Acute luminal gain 1.46 0.4 mm
Late luminal loss 0.26 0.4 mm
Late loss index 0.156 0.28
*MLD, minimal luminal diameter.
aPlus or minus values are means6 SD.
bExcludes occluded stents.
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encouraging that the use of prolonged combined anti-
platelet therapy in the START trial [27] resulted in no
late clinical thrombotic events and that the frequency of
total occlusions at 8-mo angiographic follow-up was
similar in the placebo (3.7%) and irradiated groups
(4.0%). This finding is consistent with those of the non-
radiation study cited earlier.
As noted earlier, total occlusions, diffuse lesions, and
location in a saphenous vein graft carry a high risk of
recurrence after a second PTCA for in-stent restenosis, as
do such clinical factors as diabetes [20,34]. While we do
not have a control group for comparison, our observed
target site restenosis rate of 10% and target vessel revas-
cularization rate of 19.4% is encouraging, given that 27
of 36 (75%) of our patients had at least one of these risk
factors. This study confirms the START study findings
that the user-friendlier beta-radiation appears to be as
effective in the treatment of in-stent restenosis as
gamma-radiation. Despite theoretical concerns regarding
the steeper dose falloff profile with beta-radiation, there
does not seem to be an excess of edge recurrences
compared with the gamma trials, and, unlike gamma
sources, there is the advantage of lower-risk exposure to
the patient and laboratory personnel [21,35]. Overall, the
study shows that beta-radiation therapy can be integrated
easily into the conventional catheter laboratory setting,
with easy-to-follow dosimetry protocols without the need
for intravascular ultrasonography.
Limitations of the Study
This is a relatively small study, without a control
group for direct comparison. Nevertheless, we believe
that our findings compare favorably with previously doc-
umented results on repeated interventions for in-stent
restenosis and are consistent with those of other pub-
lished series on intracoronary radiation therapy.
CONCLUSIONS
Intracoronary beta-irradiation is a breakthrough treat-
ment for in-stent restenosis after balloon angioplasty,
with encouragingly low rates of target lesion restenosis
and need for target vessel revascularization. This benefit,
however, is diminished by problems with the edge effect
and late stent occlusion. The solution to these problems
will lie, most probably, in minimizing the geographic
miss rate by careful attention to balloon and source train
placement, the availability of longer source trains, and
continuing combined antiplatelet therapy for longer pe-
riods of time.
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